<p>隨着美國股市在波動期中航行，主要指數因對人工智能泡沫的擔憂和即將發佈的經濟數據而收盤下跌，投資者正在探索多樣化的機會。便士股票通常與較小或較新的公司相關，提供了一條獨特的投資途徑，結合了可負擔性和潛在增長。儘管被視為過時的術語，這些股票仍然通過提供進入可能具有強大財務狀況和增長潛力的公司的機會而保持相關性，且價格較低。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器的 342 只股票的完整列表。</p>
<p>我們將查看篩選工具中的一些最佳選擇。</p>
<h2>Oramed Pharmaceuticals (ORMP)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 專注於利用技術平台進行治療性蛋白質的口服遞送的製藥解決方案的研究與開發，市值約為 1.2259 億美元。</p>
<p><strong>運營：</strong> Oramed Pharmaceuticals Inc. 尚未報告任何具體的收入細分。</p>
<p><strong>市值：</strong> $122.59M</p>
<p>Oramed Pharmaceuticals Inc. 以 1.2259 億美元的市值在便士股票領域中呈現出引人注目的案例，因其強大的財務狀況和近期的盈利能力。該公司無債務，短期資產為 1.361 億美元，足以覆蓋短期和長期負債。在過去一年中，Oramed 的收益激增了 882.1%，顯著超過行業平均水平，同時保持了 2.8 倍的低市盈率，而美國市場的市盈率為 19 倍。儘管收入來源有限（200 萬美元），其戰略性權利協議和分紅聲明顯示出對未來增長前景的信心。</p>
<ul>
<li>點擊這裏瞭解 Oramed Pharmaceuticals 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>在這裏瞭解 Oramed Pharmaceuticals 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP 財務狀況分析截至 2025 年 12 月</p>
<h2>Smart Sand (SND)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Smart Sand, Inc. 為壓裂砂客户提供從礦山到井場的支撐劑供應和物流解決方案，市值為 1.7461 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其砂石部門，貢獻了 3.3132 億美元，另外還有 416 萬美元來自 Smartsystems。</p>
<p><strong>市值：</strong> $174.61M</p>
<p>Smart Sand, Inc. 以 1.7461 億美元的市值最近實現了盈利，報告第三季度收入為 9278 萬美元，淨收入為 300 萬美元。該公司保持了 3% 的滿意淨債務與股本比率，並在過去五年中減少了債務。儘管股本回報率較低，僅為 1.6%，Smart Sand 的資深董事會和管理團隊提供了穩定性，而短期資產超過了短期和長期負債。最近的公告包括特別現金分紅和總計 2.55% 的股票回購，反映出在收益增長波動趨勢中的股東價值倡議。</p>
<ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Smart Sand 的表現。</li>
<li>在我們的歷史數據報告中探索 Smart Sand 的表現隨時間的變化。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis"/></p>
<p>SND 債務與股本歷史及分析截至 2025 年 12 月</p>
<h2>MariMed (MRMD)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MariMed Inc. 從事在美國和國際上種植、生產和銷售品牌大麻產品，市值為 4352 萬美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其品牌大麻產品的種植、加工和銷售，產生了 1.5738 億美元的收入。</p>
<p><strong>市值：</strong> $43.52M</p>
<p>MariMed Inc. 以 4352 萬美元的市值在充滿挑戰的便士股票市場中通過擴展產品線和市場覆蓋面而努力。最近的舉措包括推出新產品如 Bundle Up Betty's，並通過戰略合作伙伴關係進入大麻衍生的 THC 市場，這可能增強品牌知名度。儘管這些努力，MariMed 仍然處於虧損狀態，2025 年第三季度淨虧損為 295 萬美元，且在五年內虧損不斷增加。該公司的高淨債務與股本比率為 96.4%，帶來了財務風險，儘管它受益於經驗豐富的董事會和管理團隊指導其戰略前進。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 MariMed 的動態。</li>
<li>查看我們的增長表現報告，以獲取 MariMed 未來的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis"/></p>
<p>MRMD 債務與股本歷史及分析截至 2025 年 12 月</p>
<h2>關鍵要點</h2>
<ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 339 家更多公司供您探索。點擊這裏揭開我們精心策劃的 342 只美國便士股票名單。</li>
<li>尋找新視角？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現等各個方面努力。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>移動基礎設施用於國防和災難應對</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達服務，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

Oramed制藥

<p>這篇文章強調了在美國市場波動中有前景的低價股，重點關注了 Oramed Pharmaceuticals、Smart Sand 和 MariMed。Oramed 的財務狀況良好，市值為 1.2259 億美元，且盈利增長顯著。Smart Sand 的市值為 1.7461 億美元，已實現盈利並宣佈了股東價值倡議。MariMed 的市值為 4352 萬美元，儘管面臨財務挑戰，仍在擴展其大麻產品線。文章強調了這些低價股的潛在增長和相關風險</p>

<p>As the U.S. stock market navigates a period of volatility, with major indexes closing lower amid AI bubble concerns and upcoming economic data releases, investors are exploring diverse opportunities. Penny stocks, often associated with smaller or newer companies, offer a unique investment avenue that combines affordability with potential growth. Despite being considered an outdated term, these stocks remain relevant by providing access to companies that may have strong financials and growth potential at lower price points.</p>
<div class="lb-trans"><p>隨着美國股市在波動期中航行，主要指數因對人工智能泡沫的擔憂和即將發佈的經濟數據而收盤下跌，投資者正在探索多樣化的機會。便士股票通常與較小或較新的公司相關，提供了一條獨特的投資途徑，結合了可負擔性和潛在增長。儘管被視為過時的術語，這些股票仍然通過提供進入可能具有強大財務狀況和增長潛力的公司的機會而保持相關性，且價格較低。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 342 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器的 342 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中的一些最佳選擇。</p>
</div><h2>Oramed Pharmaceuticals (ORMP)</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals (ORMP)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins and has a market cap of approximately $122.59 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 專注於利用技術平台進行治療性蛋白質的口服遞送的製藥解決方案的研究與開發，市值約為 1.2259 億美元。</p>
</div><p><strong>Operations:</strong> Oramed Pharmaceuticals Inc. has not reported any specific revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Oramed Pharmaceuticals Inc. 尚未報告任何具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> $122.59M</p>
<div class="lb-trans"><p><strong>市值：</strong> $122.59M</p>
</div><p>Oramed Pharmaceuticals Inc., with a market cap of US$122.59 million, presents an intriguing case in the penny stock realm due to its robust financial position and recent profitability. The company is debt-free, with short-term assets of US$136.1 million comfortably covering both short- and long-term liabilities. Over the past year, Oramed's earnings surged by 882.1%, significantly outpacing industry averages, while maintaining a low price-to-earnings ratio of 2.8x compared to the broader US market's 19x. Despite limited revenue streams (US$2 million), its strategic Rights Agreement and dividend declaration signal confidence in future growth prospects.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. 以 1.2259 億美元的市值在便士股票領域中呈現出引人注目的案例，因其強大的財務狀況和近期的盈利能力。該公司無債務，短期資產為 1.361 億美元，足以覆蓋短期和長期負債。在過去一年中，Oramed 的收益激增了 882.1%，顯著超過行業平均水平，同時保持了 2.8 倍的低市盈率，而美國市場的市盈率為 19 倍。儘管收入來源有限（200 萬美元），其戰略性權利協議和分紅聲明顯示出對未來增長前景的信心。</p>
</div><ul>
<li>Click here to discover the nuances of Oramed Pharmaceuticals with our detailed analytical financial health report.</li>
<li>Learn about Oramed Pharmaceuticals' historical performance here.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Oramed Pharmaceuticals 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>在這裏瞭解 Oramed Pharmaceuticals 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ORMP 財務狀況分析截至 2025 年 12 月</p>
</div><h2>Smart Sand (SND)</h2>
<div class="lb-trans"><h2>Smart Sand (SND)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Smart Sand, Inc. offers mine to wellsite proppant supply and logistics solutions for frac sand customers, with a market cap of $174.61 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Smart Sand, Inc. 為壓裂砂客户提供從礦山到井場的支撐劑供應和物流解決方案，市值為 1.7461 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Sand segment, contributing $331.32 million, with an additional $4.16 million from Smartsystems.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其砂石部門，貢獻了 3.3132 億美元，另外還有 416 萬美元來自 Smartsystems。</p>
</div><p><strong>Market Cap:</strong> $174.61M</p>
<div class="lb-trans"><p><strong>市值：</strong> $174.61M</p>
</div><p>Smart Sand, Inc., with a market cap of US$174.61 million, has recently turned profitable, reporting third-quarter revenue of US$92.78 million and net income of US$3 million. The company maintains a satisfactory net debt to equity ratio of 3% and has reduced its debt over the past five years. Despite low return on equity at 1.6%, Smart Sand's seasoned board and management team provide stability, while short-term assets exceed both short- and long-term liabilities. Recent announcements include a special cash dividend and share buybacks totaling 2.55% under its repurchase plan, reflecting shareholder value initiatives amidst fluctuating earnings growth trends.</p>
<div class="lb-trans"><p>Smart Sand, Inc. 以 1.7461 億美元的市值最近實現了盈利，報告第三季度收入為 9278 萬美元，淨收入為 300 萬美元。該公司保持了 3% 的滿意淨債務與股本比率，並在過去五年中減少了債務。儘管股本回報率較低，僅為 1.6%，Smart Sand 的資深董事會和管理團隊提供了穩定性，而短期資產超過了短期和長期負債。最近的公告包括特別現金分紅和總計 2.55% 的股票回購，反映出在收益增長波動趨勢中的股東價值倡議。</p>
</div><ul>
<li>Get an in-depth perspective on Smart Sand's performance by reading our balance sheet health report here.</li>
<li>Explore historical data to track Smart Sand's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Smart Sand 的表現。</li>
<li>在我們的歷史數據報告中探索 Smart Sand 的表現隨時間的變化。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/1a600d62-1eb4-47af-9fd5-a2ed7cf24239/chart/debt-equity-history-analysis"/></p>
<p>SND Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>SND 債務與股本歷史及分析截至 2025 年 12 月</p>
</div><h2>MariMed (MRMD)</h2>
<div class="lb-trans"><h2>MariMed (MRMD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MariMed Inc. is involved in the cultivation, production, and sale of branded cannabis products both in the United States and internationally, with a market cap of $43.52 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MariMed Inc. 從事在美國和國際上種植、生產和銷售品牌大麻產品，市值為 4352 萬美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its cultivation, processing, and sale of branded cannabis products, generating $157.38 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其品牌大麻產品的種植、加工和銷售，產生了 1.5738 億美元的收入。</p>
</div><p><strong>Market Cap:</strong> $43.52M</p>
<div class="lb-trans"><p><strong>市值：</strong> $43.52M</p>
</div><p>MariMed Inc., with a market cap of US$43.52 million, is navigating the challenging penny stock landscape by expanding its product lineup and market reach. Recent initiatives include launching new products like Bundle Up Betty's and entering the hemp-derived THC market through strategic partnerships, which could enhance brand visibility. Despite these efforts, MariMed remains unprofitable with a net loss of US$2.95 million for Q3 2025 and increasing losses over five years. The company's high net debt to equity ratio of 96.4% poses financial risks, although it benefits from an experienced board and management team guiding its strategy forward.</p>
<div class="lb-trans"><p>MariMed Inc. 以 4352 萬美元的市值在充滿挑戰的便士股票市場中通過擴展產品線和市場覆蓋面而努力。最近的舉措包括推出新產品如 Bundle Up Betty's，並通過戰略合作伙伴關係進入大麻衍生的 THC 市場，這可能增強品牌知名度。儘管這些努力，MariMed 仍然處於虧損狀態，2025 年第三季度淨虧損為 295 萬美元，且在五年內虧損不斷增加。該公司的高淨債務與股本比率為 96.4%，帶來了財務風險，儘管它受益於經驗豐富的董事會和管理團隊指導其戰略前進。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of MariMed.</li>
<li>Review our growth performance report to gain insights into MariMed's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 MariMed 的動態。</li>
<li>查看我們的增長表現報告，以獲取 MariMed 未來的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/0640a1e6-a59c-4488-ae69-5cd2a65eb2de/chart/debt-equity-history-analysis"/></p>
<p>MRMD Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>MRMD 債務與股本歷史及分析截至 2025 年 12 月</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 339 more companies for you to explore.Click here to unveil our expertly curated list of 342 US Penny Stocks.</li>
<li>Searching for a Fresh Perspective? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 339 家更多公司供您探索。點擊這裏揭開我們精心策劃的 342 只美國便士股票名單。</li>
<li>尋找新視角？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現等各個方面努力。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難應對</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達服務，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Oramed 製藥及其他兩個值得關注的有前景的便士股